US › Healthcare

BioAge Labs, Inc (BIOA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$8.09+4.39%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$2.5M

Revenue YoY

+1.6%

Net profit

$-26.1M

EPS

$-0.58

EPS estimate

$-0.65

Net margin

-1,064.7%

EPS came in at -0.58 against a street estimate of -0.65 — a beat of 10.8%.

Key statistics

Market cap

$389.7M

Forward P/E

0.0

P/B

1.04

Book value

$8.19

EPS (TTM)

$-2.39

52-week high

$25.95

52-week low

$4.68

50-day MA

$15.24

200-day MA

$16.94

Analyst view

Analysts rate BioAge Labs, Inc a hold (0 buy, 3 hold, 1 sell out of 4) with an average price target of $35.62.

Shareholding

Insiders

2.36%

Institutions

90.46%

Largest institutional holders

Fund	Stake
Cormorant Asset Management, LLC	6.30%
Sofinnova Ventures	5.00%
BlackRock Inc	4.94%
HHG PLC	4.56%
Octagon Capital Advisors LP	3.81%
MPM Oncology Impact Management LP	3.63%
RA Capital Management, LLC	3.60%
Vanguard Capital Management, LLC	2.95%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioAge Labs, Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.